DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Analyst Outlook | Price targets range from $80 to $102, averaging $91.25, reflecting mixed sentiment as DexCom balances market leadership against competitive threats from Abbott and potential regulatory hurdles. |
Financial Headwinds | Despite robust sales of $1.04 billion in Q1 2025, DexCom faces margin challenges from quality initiatives and supply issues, prompting revised forecasts for 2026. |
Growth Catalysts | Expansion into the Type 2 diabetes market and the upcoming G7 15-day sensor launch present significant opportunities, with 6 million new covered lives expected by year-end 2025. |
Diabetes Tech Leade | DexCom dominates the continuous glucose monitoring market with strong sales growth and record new patient starts, despite facing recent margin pressures from supply chain challenges. |

Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 35.9x | 18.1x | −0.6x | |
PEG Ratio | 4.63 | −0.18 | 0.00 | |
Price / Book | 9.5x | 4.3x | 2.6x | |
Price / LTM Sales | 5.7x | 2.6x | 3.2x | |
Upside (Analyst Target) | 26.6% | 35.8% | 42.7% | |
Fair Value Upside | Unlock | −1.8% | 6.8% | Unlock |